Correspondence

Renal impairment in relation to non-steroidal anti-inflammatory drugs

Sirs, Unsworth et al have recently shown that asymptomatic, reversible impairment of renal function is common in patients with rheumatoid arthritis (RA) receiving long term non-steroidal anti-inflammatory drug (NSAID) treatment. This conclusion was derived from the observation that when NSAID treatment in 11 patients was stopped there was a significant rise in creatinine clearance, a significant fall in serum creatinine, and a trend downwards in serum urea, compared with 11 patients who continued to receive NSAIDs, in whom no such changes were seen.

We have recently undertaken a study to investigate the effects of a new NSAID (tenoxicam) on renal function in a larger number of patients. The study comprised 40 patients (four male, 36 female; mean age (SEM) 72 (1-4) years) with RA or osteoarthritis and suffering from renal impairment as defined by a creatinine clearance of 25-80 ml/min. Patients stopped their NSAID treatment for a three day (n=27) or seven day (n=13) washout period before starting tenoxicam (20 mg/day), which was continued for 12 weeks. All other drug treatment was continued as before such that low dose prednisolone was continued by seven patients and second line agents by eight. Renal function was monitored by measurement of creatinine clearance, serum creatinine, serum urea, and urine β-N-acetylg glucosaminidase/creatinine ratio at baseline (time of stopping current NSAID), week 0 (time of starting tenoxicam treatment) and weeks 4, 8, and 12 of tenoxicam treatment.

The Table shows a marked improvement in renal function during the washout period with a gradual return towards the baseline status during the period of tenoxicam treatment. In the case of serum creatinine and serum urea the mean results at week 12 were essentially the same as at baseline, whereas creatinine clearance remained higher than baseline, though not significantly.

In Unsworth's study the time patients were not receiving NSAIDs varied from three to 36 days, whereas in our study patients were only without NSAIDs for three or seven days. The 27 patients who only had a three day washout still showed a significant rise in creatinine clearance (p<0.01). This makes the effect of NSAID withdrawal on renal function even more pronounced and suggests a prostaglandin mediated mechanism. Our results in a larger patient series support the observations of Unsworth. Furthermore, our results indicate that the effect of up to 12 weeks of tenoxicam treatment on patients with renal impairment was mild and certainly no worse than for other NSAIDs as judged by comparison of results at week 12 with those at baseline, which presumably reflect the degree of renal impairment induced by the previous NSAID treatment. The latter would clearly vary in choice, dose, and duration from patient to patient.

Clinical Pharmacology Unit, (Rheumatism Research), Royal Bath Hospital, Cornwall Road, Harrogate HG1 2PS

Reference


Table

<table>
<thead>
<tr>
<th>Week No</th>
<th>No of patients continuing to receive tenoxicam</th>
<th>Creatinine clearance (ml/min)</th>
<th>NAG/creatinine</th>
<th>Serum creatinine (umol/l)</th>
<th>Serum urea (mmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>n</td>
<td>x SEM</td>
<td>n</td>
<td>x SEM</td>
</tr>
<tr>
<td>Baseline</td>
<td>—</td>
<td>37</td>
<td>48.3 2.2</td>
<td>(6)</td>
<td>(139) (39)</td>
</tr>
<tr>
<td>0</td>
<td>40</td>
<td>33</td>
<td>62.4 3.8</td>
<td>40</td>
<td>91 10</td>
</tr>
<tr>
<td>4</td>
<td>39</td>
<td>23</td>
<td>67.6 4.7</td>
<td>27</td>
<td>75 7</td>
</tr>
<tr>
<td>8</td>
<td>28</td>
<td>19</td>
<td>66.9 4.9</td>
<td>22</td>
<td>74 10</td>
</tr>
<tr>
<td>12</td>
<td>19</td>
<td>15</td>
<td>58.1 7.7</td>
<td>12</td>
<td>78</td>
</tr>
<tr>
<td>Baseline v week 0*</td>
<td>&lt;0.001</td>
<td>ND</td>
<td>&lt;0.001</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Week 0 v week 12</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

*When repeated using only results from patients completing 12 weeks' treatment the significant results remained. When repeated using only data from patients with a three day washout creatinine clearance still showed a significant change (p<0.01), but serum creatinine and serum urea did not.

NAG=β-N-acetylg glucosaminidase. ND=not determined (baseline, n=6); NS=not significant (p>0.05) paired t test.

260
Renal impairment in relation to non-steroidal anti-inflammatory drugs.
J S Dixon, R Bojar and H A Bird

doi: 10.1136/ard.47.3.260

Updated information and services can be found at:
http://ard.bmj.com/content/47/3/260.citation

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/